Literature DB >> 24236755

Recent insights into the pathogenesis of hepatic encephalopathy and treatments.

Jonathan P Sturgeon1, Debbie L Shawcross.   

Abstract

Hepatic encephalopathy (HE) encompasses a spectrum of neuropsychiatric disorders related to liver failure. The development of HE can have a profound impact on mortality as well as quality of life for patients and carers. Ammonia is central in the disease process contributing to alteration in neurotransmission, oxidative stress, and cerebral edema and astrocyte swelling in acute liver failure. Inflammation in the presence of ammonia coactively worsens HE. Inflammation can result from hyperammonemic responses, endotoxemia, innate immune dysfunction or concurrent infection. This review summarizes the current processes implicated in the pathogenesis of HE, as well as current and potential treatments. Treatments currently focus on reducing inflammation and/or blood ammonia levels and provide varying degrees of success. Optimization of current treatments and initial testing of novel therapies will provide the basis of improvement of care in the near future.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24236755     DOI: 10.1586/17474124.2014.858598

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  15 in total

1.  Microbiota facilitates the formation of the aminated metabolite of green tea polyphenol (-)-epigallocatechin-3-gallate which trap deleterious reactive endogenous metabolites.

Authors:  Shuwei Zhang; Yantao Zhao; Christina Ohland; Christian Jobin; Shengmin Sang
Journal:  Free Radic Biol Med       Date:  2018-12-19       Impact factor: 7.376

Review 2.  Ammonia Transporters and Their Role in Acid-Base Balance.

Authors:  I David Weiner; Jill W Verlander
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

Review 3.  Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.

Authors:  Rune Gangsoy Kristiansen
Journal:  Metab Brain Dis       Date:  2016-09-21       Impact factor: 3.584

4.  Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.

Authors:  Harry D Zacharias; Antony P Zacharias; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

5.  Minimal hepatic encephalopathy characterized by parallel use of the continuous reaction time and portosystemic encephalopathy tests.

Authors:  M M Lauridsen; O B Schaffalitzky de Muckadell; H Vilstrup
Journal:  Metab Brain Dis       Date:  2015-05-29       Impact factor: 3.584

Review 6.  Management of Neurologic Manifestations in Patients with Liver Disease.

Authors:  José M Ferro; Pedro Viana; Patrícia Santos
Journal:  Curr Treat Options Neurol       Date:  2016-08       Impact factor: 3.598

7.  Acetyl-L-carnitine for patients with hepatic encephalopathy.

Authors:  Arturo J Martí-Carvajal; Christian Gluud; Ingrid Arevalo-Rodriguez; Cristina Elena Martí-Amarista
Journal:  Cochrane Database Syst Rev       Date:  2019-01-05

8.  Hepatic encephalopathy coexists with acquired chronic hepatocerebral degeneration.

Authors:  Feng-Zhen Huang; Xuan Hou; Tie-Qiao Zhou; Si Chen
Journal:  Neurosciences (Riyadh)       Date:  2015-07       Impact factor: 0.906

9.  Commiphora molmol Modulates Glutamate-Nitric Oxide-cGMP and Nrf2/ARE/HO-1 Pathways and Attenuates Oxidative Stress and Hematological Alterations in Hyperammonemic Rats.

Authors:  Ayman M Mahmoud; Sultan Alqahtani; Sarah I Othman; Mousa O Germoush; Omnia E Hussein; Gadh Al-Basher; Jong Seong Khim; Maha A Al-Qaraawi; Hanan M Al-Harbi; Abdulmannan Fadel; Ahmed A Allam
Journal:  Oxid Med Cell Longev       Date:  2017-06-28       Impact factor: 6.543

10.  To Break or to Brake Neuronal Network Accelerated by Ammonium Ions?

Authors:  Vladimir V Dynnik; Alexey V Kononov; Alexander I Sergeev; Iliya Y Teplov; Arina V Tankanag; Valery P Zinchenko
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.